Today, we have to share some bad news about Organovo and its liver tissue bioprinting program. Present state and future steps Organovo, a biotechnology company currently valued at $45M and most well-known for researching bioprinting technologies – the creation of artificial organs – has recently announced that it is suspending its artificial liver tissue program…

© 2018 - LIFE EXTENSION ADVOCACY FOUNDATION
Privacy Policy / Terms Of Use

       Powered by MMD